| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50419-0050-14 | 50419-0050 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Mar 5, 1991 | Sep 21, 2012 | No Longer Used | ||
| 62856-0797-01 | 62856-0797 | Palonosetron hydrochloride | Aloxi | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 28, 2014 | Oct 31, 2022 | No Longer Used |
| 50742-0354-01 | 50742-0354 | MESNA | MESNA | 400.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Oral | Jan 14, 2025 | In Use | |
| 55154-2872-05 | 55154-2872 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 19, 2010 | Aug 31, 2013 | No Longer Used |
| 63187-0379-06 | 63187-0379 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 30, 2023 | In Use | |
| 82650-0144-01 | 82650-0144 | PALONOSETRON HYDROCHLORIDE | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Mar 23, 2018 | In Use | |
| 68084-0879-95 | 68084-0879 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Sep 30, 2015 | In Use | |
| 51655-0933-87 | 51655-0933 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 20, 2022 | In Use | |
| 72205-0248-01 | 72205-0248 | Dexrazoxane | Dexrazoxane | 500.0 mg/50mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Apr 9, 2025 | In Use | |
| 63850-0003-01 | 63850-0003 | Ondansetron Tablets | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 55513-0148-01 | 55513-0148 | Epoetin alfa | Epogen | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 16, 1993 | In Use | ||
| 50090-1718-00 | 50090-1718 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2015 | In Use | |
| 50633-0220-04 | 50633-0220 | Uridine triacetate | VISTOGARD | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 31, 2024 | In Use | |
| 68071-1904-06 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2017 | In Use | |
| 55513-0823-01 | 55513-0823 | Epoetin alfa | Epogen | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Mar 3, 1997 | Jul 31, 2010 | No Longer Used | |||
| 55390-0122-10 | 55390-0122 | Cyclosporine | Cyclosporine | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Intravenous | Dec 15, 1999 | Feb 29, 2012 | No Longer Used | |
| 00143-2422-01 | 00143-2422 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2008 | Dec 31, 2014 | In Use |
| 00069-1441-40 | 00069-1441 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | May 4, 2013 | Dec 31, 2017 | No Longer Used |
| 00904-6551-61 | 00904-6551 | Ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
| 71930-0018-52 | 71930-0018 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 6, 2020 | In Use | |
| 42023-0151-01 | 42023-0151 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 4, 2013 | Feb 25, 2020 | In Use | |
| 59353-0004-10 | 59353-0004 | Epoetin alfa-epbx | RETACRIT | 4000.0 [iU]/mL, 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
| 60760-0637-20 | 60760-0637 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 13, 2018 | Dec 31, 2021 | In Use |
| 51672-4109-08 | 51672-4109 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 28, 2011 | In Use | |
| 00173-0447-02 | 00173-0447 | Ondansetron Hydrochloride | Zofran | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 11, 1993 | Aug 21, 2013 | No Longer Used |
Found 11888 results — Export these results
Home